paige_pharma said:Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.
Bookmarking. The distinction being drawn above is the one nobody else makes. Taking it to my next appointment.
Adding the clinical framing, because it changes how the question reads.
Kidney function labs on renal function — good news for anyone concerned about renal effects:
| Marker | Baseline | Month 6 | Ref Range |
|---|---|---|---|
| eGFR | 86 | 93 | >60 |
| Creatinine | 1.3 | 0.9 | 0.7-1.3 |
| BUN | 18 | 15 | 7-20 |
| UACR | 71 | 24 | <30 |
The FLOW trial demonstrated renal protective effects of semaglutide. My nephrologist is encouraged by the UACR improvement especially.
Dr.KarenChen said:Steady state is the thing most people miss.
I read this differently from Dr.KarenChen, on substance rather than tone. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.
I would rather be corrected than agreed with, if it comes to it.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemDr.RenalNash said:FLOW is the relevant trial and it reported a meaningful reduction in kidney-disease progression and related death in people with type 2 diabetes and…
GFR trending upward on renal function — encouraging for those with mild CKD concerns:
Baseline eGFR: 74 → Month 6: 84 → Month 12: 87
The FLOW trial confirmed renal benefits of semaglutide: 24% reduction in kidney disease progression. My nephrologist is now actively recommending GLP-1 therapy for appropriate CKD patients. This could be a paradigm shift in nephrology.
Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Tagging this one for the weekly digest.